संपर्क करें
कम्पनी के बारे में
Alzeca Biosciences develops novel advanced imaging agents for the early diagnosis of neurodegenerative diseases, including Alzheimer’s Disease. Alzheimer’s affects approximately 5.5M Americans at a cost of over $226 billion in care, and affects over 27 million patients worldwide. Its incidence is projected to quadruple by 2050 with costs exceeding $1 trillion in the US alone, unless a more effective diagnostic and treatment method is achieved.
US
अनजान
अनजान
सत्यापित कंपनी नहीं
व्यापार पारदर्शिता
- कंपनी की जानकारी सत्यापित नहीं की
- समीक्षा के लिए अपने ग्राहकों से पूछें
- नकारात्मक समीक्षाओं का जवाब नहीं दिया